Patents by Inventor Philip Pienkos

Philip Pienkos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOMINANT NEGATIVE LIGAND DRUG DISCOVERY SYSTEM
    Publication number: 20080064039
    Abstract: The present invention relates to novel methods of designing and optimizing polypeptide based ligands which are useful for altering and/or modulating cellular signaling cascades which have become dysregulated. The therapeutic dominant negative ligands (DNLs) and DNL variants designed by the methods herein have useful applications in medicine, diagnostics and drug discovery.
    Type: Application
    Filed: July 3, 2007
    Publication date: March 13, 2008
    Inventors: Philip Pienkos, Daniel Monticello
  • Pan-HER antagonists and methods of use
    Publication number: 20060154333
    Abstract: The present invention features human epidermal receptor (HER) antagonists. These antagonists are polypeptide variants of ligands of HER. The HER ligand polypeptide variants of the invention possess Pan-HER antagonistic properties and can inhibit at least one HER-mediated biological activity of one or more HER subtypes, such as inhibition of the receptor's kinase activation activity and subsequently, cell proliferation. Such polypeptide variants, and nucleic acids encoding these polypeptide variants can be used therapeutically in situations in which inhibition of HER activity is indicated.
    Type: Application
    Filed: June 30, 2005
    Publication date: July 13, 2006
    Inventors: Philip Pienkos, Daniel Monticello
  • Epidermal growth factor receptor antagonists and methods of use
    Publication number: 20060014690
    Abstract: The present invention features epidermal growth factor receptor (EGFR) antagonists. These EGFR antagonists are polypeptide variants of ligands of EGFR. The EGFR ligand polypeptide variants of the invention possess EGFR antagonistic properties and can inhibit at least one EGFR-mediated biological activity such as inhibition of the receptor's kinase activation activity and subsequently, cell proliferation. Such polypeptide variants, and nucleic acids encoding these polypeptide variants can be used therapeutically in situations in which inhibition of EGFR activity is indicated.
    Type: Application
    Filed: June 30, 2005
    Publication date: January 19, 2006
    Inventors: Jeffrey Bishop, A. Loomis, Daniel Monticello, Philip Pienkos
  • Epidermal growth factor agonists and methods of use
    Publication number: 20050032162
    Abstract: The present invention features polypeptides that have at least 90% amino acid identity to wild-type epidermal growth factor, and also have epidermal growth factor biological activity that is greater than the biological activity of wild-type epidermal growth factor.
    Type: Application
    Filed: April 8, 2004
    Publication date: February 10, 2005
    Inventors: Wayne Coco, Philip Pienkos, A. Loomis